Adaptive design clinical trials: A review of the literature and ClinicalTrials.gov

BMJ Open

Volumn 8, Issue 2, 2018, Pages

  Bothwell, Laura E ^a   Avorn, Jerry ^a   Khan, Nazleen F ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

adaptive design; clinical trial; data monitoring committee; EMA; FDA; flexible design; history; interim analysis; policy; regulation; review

Indexed keywords

NEW DRUG;

ADAPTIVE CLINICAL TRIAL (TOPIC); ARTICLE; CLINICAL FEATURE; COCHRANE LIBRARY; DRUG APPROVAL; EMBASE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDLINE; PROFESSIONAL STANDARD; UNITED STATES; WEB OF SCIENCE; METHODOLOGY; PROCEDURES; STATISTICS; TRENDS;

ADAPTIVE CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH DESIGN; STATISTICS AS TOPIC;

EID: 85051986263     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-018320     Document Type: Article

References (45)

1. Bothwell LE, Greene JA, Podolsky SH, et al. Assessing the gold standard-lessons from the history of RCTs. N Engl J Med 2016;374:2175-81
2. United States Government. Rules committee print 114-67, text of House amendment to the Senate, amendment to H. R. 34, Tsunami Warning, Education, and Research Act of 2015, 2016:162-3. 114th Congress. http:// docs. house. gov/ billsthisweek/ 20161128/ CPRT-114-HPRT-RU00-SAHR34. pdf
3. Simon R. Adaptive treatment assignment methods and clinical trials. Biometrics 1977;33:743-9
4. Hoel DG, Sobel M, Weiss GH. A survey of adaptive sampling for clinical trials. In: Elashoff RM, eds. Perspectives in Biometrics. New York: Academic Press, 1975:30
5. U. S. Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: Adaptive design clinical trials for drugs and biologics (Draft Guidance). MD: Silver Spring, 2010
6. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979;35:183-97
7. Simon R. A decade of progress in statistical methodology for clinical trials. Stat Med 1991;10:1789-817
8. Emerson SS. Issues in the use of adaptive clinical trial designs. Stat Med 2006;25:3270-96
9. Meurer WJ, Lewis RJ, Tagle D, et al. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med 2012;60:451-7
10. Chow S-C, Chang M. Adaptive design methods in clinical trials. Boca Raton: Chapman & Hall/CRC, 2007
11. Chin RY. Adaptive and flexible clinical trials. Boca Raton: CRC Press, 2012
12. Emerson SS, Fleming TR. Adaptive methods: Telling "the rest of the story". J Biopharm Stat 2010;20:1150-65
13. Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive designs in clinical drug development-an executive summary of the PhRMA Working Group. J Biopharm Stat 2006;16:275-83
14. Chow S-C, Chang M. Adaptive design methods in clinical trials-a review. Orphanet J Rare Dis 2008;3:11-13
15. Meurer WJ, Legocki L, Mawocha S, et al. Attitudes and opinions regarding confirmatory adaptive clinical trials: A mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials 2016;17:373
16. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74
17. Morgan CC, Huyck S, Jenkins M, et al. Adaptive design: results of 2012 survey on perception and use. Therap Innov Reg Sci 2014;48:473-81
18. Dimairo M, Julious SA, Todd S, et al. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials 2015;16:585
19. Hatfield I, Allison A, Flight L, et al. Adaptive designs undertaken in clinical research: A review of registered clinical trials. Trials 2016;17:150
20. Lin M, Lee S, Zhen B, et al. CBER's experience with adaptive design clinical trials. Therap Innov Reg Sci 2016;50:195-203
21. Yang X, Thompson L, Chu J, et al. Adaptive design practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013. Therap Innov Reg Sci 2016:50: 710-717
22. Chow S-C, Liu J-P. Design and analysis of clinical trials. 3rd edn. Hoboken, NJ: John Wiley, 2014
23. Chow S-C. Adaptive clinical trial design. Annu Rev Med 2014;65:405-15
24. U. S. Food & Drug Administration. Drugs@FDA: FDA Approved Drug Products. 2016 http://www. accessdata. fda. gov/ scripts/ cder/ drugsatfda
25. European Medicines Agency. European public assessment reports [Internet]. London: EMA, 2016. http://www. ema. europa. edu/ ema/ index. jsp? curl= pages/ medicines/ landing/ epar- search. jsp& mid= WC0b01ac058001d124
26. Karlberg JPE. Biomedical publication trends by geographic area. Clin Trial Mag 2010;2:682-701
27. Petryna A. When experiments travel: clinical trials and the global search for human subjects. Princeton: Princeton University Press, 2009
28. Meinert CL. Clinical trials: design conduct and analysis. 2nd edn. Oxford: Oxford University Press, 2012
29. Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003-2008. JAMA 2010;303:137-43
30. Jenkins JK. CDER new drug review: 2015 update [Internet]. [Place unknown]: FDA center for drug evaluation and research. 2015 http: //www. fda. gov/d ownl oads /Abo utFD A/Ce nter sOff?ices/ OfficeofMedicalProdu ctsa ndTo bacco/ CDE R/ UCM477020. pdf (cited 2016 Jun 26)
31. Downing NS, Aminawung JA, Shah ND, et al. Regulatory review of novel therapeutics-comparison of three regulatory agencies. N Engl J Med 2012;366:2284-93
32. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
33. European Medicines Agency. Assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix [Internet]. London: EMA, 2012:45. http://www. ema. europa. eu/ docs/ en- GB/ document- library/ Herbal--- HMPC- assessment- report/ 2013/ 02/ WC500138812. pdf (cited 2016 Jul 5)
34. Bauer P, Einfalt J. Application of adaptive designs-a review. Biom J 2006;48:493-506
35. Elsäßer A, Regnstrom J, Vetter T, et al. Adaptive clinical trial designs for European marketing authorization: A survey of scientific advice letters from the European Medicines Agency. Trials 2014;15:383
36. Stevely A, Dimairo M, Todd S, et al. An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: A methodological systematic review. PLoS One 2015;10:e0141104
37. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomized controlled trials and a proposed extension to the CONSORT guidelines. BMC Med Res Methodol 2017;17:108
38. Dimairo M, Boote J, Julious SA, et al. Missing steps in a staircase: A qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials 2015;16:430
39. Chow S-C, Corey R, Lin M. On the independence of data monitoring committee in adaptive design clinical trials. J Biopharm Stat 2012;22:853-67
40. United states food and drug administration center for drug evaluation and research, center for biologics evaluation and research. Rockville, MD: Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees, 2006
41. Gallo P, Anderson K, Chuang-Stein C, et al. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J Biopharm Stat 2010;20:1115-24
42. Hung HM, O'Neill RT, Wang SJ, et al. A regulatory view on adaptive/ flexible clinical trial design. Biom J 2006;48:565-73
43. Kairalla JA, Coffey CS, Thomann MA, et al. Adaptive trial designs: A review of barriers and opportunities. Trials 2012;13:145
44. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-guided adaptive trial designs in phase II and phase III: A methodological review. PLoS One 2016;11:e0149803-30
45. Emerson SC, Rudser KD, Emerson SS. Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings. Stat Med 2011;30:1199-217